Clin2
NCT06861010Possibly a fitRecruiting

Ondansetron to prevent pancreatitis after ERCP

Pancreatic Diseases

Treatments studied

Part of Digestive system clinical trials.

This trial tests whether ondansetron, a medicine that helps control nausea and vomiting, can reduce the risk of pancreatitis (inflammation of the pancreas) after an ERCP procedure. If you are scheduled for an ERCP and do not have certain health issues, you may be able to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
44 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You are scheduled for ERCP due to a suspected pancreas or bile duct problem.
  • Your blood amylase and lipase levels are normal before the procedure.
  • You do not have a history of pancreatitis before the ERCP.
  • You have not had prior treatments on your bile or pancreatic duct opening (like cutting, stretching, or stenting).
  • You are not pregnant or nursing.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06860984Recruiting· Phase 3
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

This phase 3 trial tests duloxetine for preventing pancreatitis after ERCP in adults with normal baseline amylase/lipase and without certain comorbidities.

Tanta
NCT05667987Recruiting
Lidocaine to help prevent pancreas inflammation after ERCP

This study tests whether giving lidocaine during an ERCP procedure can lower the risk of a painful complication called pancreatitis. If you’re scheduled for ERCP with a “never-treated” opening, this trial may see if lidocaine helps you avoid post-procedure pancreas inflammation.

Paris
NCT05252754Recruiting· Phase 3
Medicines to prevent pancreas swelling after ERCP

This Phase 3 study tests whether putting an anti-inflammatory medicine into the rectum (indomethacin) plus taking an immune-suppressing pill (tacrolimus) works better than using the two medicines in a different combination to prevent pancreatitis after an ERCP procedure. If you qualify, you may be assigned to one of the treatment options to lower your risk of post-ERCP pancreas inflammation.

Baltimore, Maryland
NCT07781722Not yet recruiting· Phase 4
Tacrolimus to prevent pancreatitis after ERCP

This trial tests whether a drug called tacrolimus can reduce the risk of pancreatitis (inflammation of the pancreas) after a procedure called ERCP, which is used to diagnose and treat problems in the bile ducts or pancreas. If you are scheduled for an ERCP, this study may help prevent a common complication.

Amsterdam
NCT07776561Recruiting
Short-stay IV fluids to prevent pancreatitis after ERCP

This trial tests whether giving extra IV fluids before, during, and after an ERCP procedure can help prevent a common complication called post-ERCP pancreatitis (inflammation of the pancreas). If you are scheduled for an ERCP, you may be eligible to participate.

Westmead, New South Wales
NCT07330284Recruiting
Cold water rinse to prevent pancreatitis after ERCP

This trial tests whether rinsing the pancreas with cold water during ERCP can reduce the risk of pancreatitis, a common complication. The treatment is added to the standard medicine (indomethacin) to see if it offers extra protection.

Kansas City, Kansas

Hear when a new Pancreatic Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.